Indicators of functional status for primary malignant brain tumour patients

Canadian Journal of Neurological Sciences

Volumn 32, Issue 1, 2005, Pages 50-56

  Bussière, Miguel ^a   Hopman, Wilma ^b,c   Day, Andrew ^b   Pombo, Alicia Paris ^c   Neves, Teresa ^c   Espinosa, Francisco ^c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b KINGSTON GENERAL HOSPITAL   (Canada)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LOMUSTINE; PROCARBAZINE; TAMOXIFEN; VINCRISTINE;

ADOLESCENT; ADULT; AGED; BRAIN TUMOR; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CHI SQUARE DISTRIBUTION; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DEMOGRAPHY; FEMALE; GLIOBLASTOMA; GLIOMA; HISTOPATHOLOGY; HUMAN; KRUSKAL WALLIS TEST; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIMODALITY CANCER THERAPY; OLIGODENDROGLIOMA; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SCHOOL CHILD; SURVIVAL TIME;

EID: 14944365692     PISSN: 03171671     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0317167100016875     Document Type: Review

References (38)

1. Gaudette LA, Lee J. Statistics Canada. Cancer Incidence in Canada, 1969-1993. Ottawa: Health Statistics Division, Catalogue 82-566-XPB. Occasional, Ottawa, April 1997.
2. Chen VW, Howe HL, Wu XC, Holes JL, Correa CN (Eds). Cancer in North America, 1993-1997. Volume One: Incidence, Volume Two: Mortality. Sacramento, CA: North American Association of Central Cancer Registries, April 2000.
3. Desmeules M, Mikkelson T, Mao Y. Increasing incidence of primary malignant brain tumours: Influence of diagnostic methods. J Natl Cancer Inst 1992; 84: 442-445.
4. Riggs JE. Rising primary malignant brain tumor mortality in the elderly. Arch Neurol 1995; 52: 571-575.
5. Fernandez PM, Brem S. Malignant brain tumours in the elderly. Clin Geriatr Med 1997; 13: 327-338.
6. Fine HA. The basis for current treatment recommendations for malignant gliomas. J Neurooncol 1994; 20: 111-120.
7. Forsyth PAJ, Cairncross JG. Treatment of malignant glioma in adults. Curr Opin Neurol 1995; 8: 414-418.
8. Whittle IR. Management of primary malignant brain tumours. J Neurol Neurosurg Psychiatry 1996; 60: 2-5.
9. Chamberlain MC, Kormanik PA. Practical guidelines for the treatment of malignant gliomas. West J Med 1998; 168: 114-200.
10. Levin VA. Neuro-oncology. an overview. Arch Neurol 1999; 56: 401-403.
11. Whittle IR, Denholm SW, Gregor A. Management of patients aged over 60 years with supratentorial glioma: lessons from an audit. Surg Neurol 1991; 36: 106-111.
12. Halperin EC. Malignant gliomas in older adults with poor prognostic signs. Getting nowhere, and taking a long time to do it. Oncology 1995; 9: 229-234.
13. Curran WJ, Scott SB, Horton J, et al. Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 1993; 85: 704-710.
14. Mohan DS, Suh JH, Phan JL, et al. Outcome in elderly patients undergoing definitive surgery and radiation therapy for supratentorial glioblastoma multiforme at a tertiary care institution. Int J Radiat Oncol Biol Phys 1998; 42: 981-987.
15. Medical Research Council Brain Tumour Working Party. Prognostic factors for high-grade malignant glioma: development of a prognostic index. J Neurooncol 1990; 9: 47-55.
16. Shapiro WR, Young DF. Chemotherapy of malignant glioma. A controlled study of chemotherapy and irradiation. Arch Neurol 1976; 33: 494-500.
17. Hochberg FH, Linggood R, Wolfson L, Baker WH, Kornblith P. Quality and duration of survival in glioblastoma multiforme. Combined surgical, radiation, and lomustine therapy. JAMA 1979; 241: 1016-1018.
18. Shapiro WR. Treatment of neuroectodermal brain tumours. Ann Neurol 1982; 12: 231-237.
19. Ammimrati M, Vick N, Liao Y, Ciric I, Mikhael M. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 1987; 21: 201-206.
20. Leibel SA, Gutin PH, Wara WM, et al. Survival and quality of life after interstitial implantation of removable high activity Iodine-125 sources for the treatment of patients with recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1989; 17: 1129-1139.
21. Sachsenheimer W, Piotrowski W, Bimmler T. Quality of life in patients with intracranial tumours on the basis of Karnofsky's performance status. J Neurooncol 1992; 13: 177-181.
22. Choksey MS, Valentine A, Shawdon H. Computed tomography in the diagnosis of malignant brain tumours: do all patients require biopsy? J Neurol Neurosurg Psychiatry 1989; 52: 821-825.
23. Karnofsky DA. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, Burchenal JH (Eds). Evaluation of Chemotherapeutic Agents. New York: Columbia Univ. Press. 1949:191-205.
24. Coscarelli Shag C, Heinrich RL, Ganz PA. Karnofsky performance status revisited: reliability, validity and guidelines. J Clin Oncol 1984; 2: 187-193.
25. Mor V, Laliberte L, Morris J N, Wiemann M. The Karnofsky status scale: an examination of its reliability and validity in a research setting. Cancer 1984; 53: 2002-2007.
26. Barker FG, Prados MD, Chang SM, et al. Radiation response and survival time in patients with glioblastoma multiforme. J Neurosurg 1996; 84: 442-448.
27. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1993; 71: 2585-2597.
28. Hildebrand J, Sahmoud T, Mignolet F, Brucher JM, Afra D, EORTC Brain Tumour Group. Adjuvant therapy with dibromodulcitol and BCNU increases survival of adults with malignant gliomas. Neurology 1994; 44: 1479-1483.
29. DeAngelis LM, Burger PC, Green SB, Cairncross JG. Malignant glioma: who benefits from adjuvant chemotherapy? Ann Neurol 1998; 44: 691-695.
30. Cairncross JG. MacDonald DR. Successful chemotherapy for recurrent malignant oligodendrogliomas. Ann Neurol 1988; 23: 360-364.
31. MacDonald DR, Gasper LE, Cairncross JG. Successful chemotherapy for newly diagnosed aggressive oligodendroglioma. Ann Neurol 1990; 27: 573-574.
32. Cairncross JG, MacDonald DR, Ludwin S, et al. Chemotherapy for anaplastic oligodendroglioma J Clin Oncol 1994; 12: 2013-2021.
33. Yung WKA, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolamide in patients with anaplastic astrocytoma or anaplastic oligodcndroalioma at first relapse. J Clin Oncol 1999; 17: 2762-2771.
34. Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolamide vs. probarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593.
35. Stupp R, Dietrich P, Kraljevic SO, et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 2002; 20: 1375-1382.
36. Mackworth N, Fobair P, Prados MD. Quality of life self-reports from 200 brain tumor patients: comparisons with Karnofsky performance scores. J Neurooncol 1992; 14: 243-253.
37. Weitzner MA, Meyers CA. Cognitive functioning and quality of life in malignant glioma patients: a review of the literature. Psychooncology 1997; 6: 167-177.
38. Aiken RD. Quality of life in patients with malignant gliomas. Semin Oncol 1994; 21: 273-275.